Targeting mutant KRAS for anticancer therapeutics: A review of novel small molecule modulators

Yuanxiang Wang, Christine E. Kaiser, Brendan Frett, Hong Yu Li

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The RAS proteins play a role in cell differentiation, proliferation, and survival. Aberrant RAS signaling has been found to play a role in 30% of all cancers. KRAS, a key member of the RAS protein family, is an attractive cancer target, as frequent point mutations in the KRAS gene render the protein constitutively active. A number of attempts have been made to target aberrant KRAS signaling by identifying small molecule compounds that (1) are synthetic lethal to mutant KRAS, (2) block KRAS/GEF interactions, (3) inhibit downstream KRAS effectors, or (4) inhibit the post-translational processing of RAS proteins. In addition, inhibition of novel targets outside the main KRAS signaling pathway, specifically the cell cycle related kinase PLK1, has been shown have an effect in cells that harbor mutant KRAS. Herein we review the use of various high-throughput screening assays utilized to identify new small-molecule compounds capable of targeting mutant KRAS-driven cancers.

Original languageEnglish (US)
Pages (from-to)5219-5230
Number of pages12
JournalJournal of Medicinal Chemistry
Volume56
Issue number13
DOIs
StatePublished - Jul 11 2013

Fingerprint

High-Throughput Screening Assays
Neoplasms
Proteins
Post Translational Protein Processing
Point Mutation
Cell Differentiation
Cell Survival
Cell Cycle
Phosphotransferases
Therapeutics
Cell Proliferation

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Targeting mutant KRAS for anticancer therapeutics : A review of novel small molecule modulators. / Wang, Yuanxiang; Kaiser, Christine E.; Frett, Brendan; Li, Hong Yu.

In: Journal of Medicinal Chemistry, Vol. 56, No. 13, 11.07.2013, p. 5219-5230.

Research output: Contribution to journalArticle

Wang, Yuanxiang ; Kaiser, Christine E. ; Frett, Brendan ; Li, Hong Yu. / Targeting mutant KRAS for anticancer therapeutics : A review of novel small molecule modulators. In: Journal of Medicinal Chemistry. 2013 ; Vol. 56, No. 13. pp. 5219-5230.
@article{bdef549d8540432a87f5e703311e166f,
title = "Targeting mutant KRAS for anticancer therapeutics: A review of novel small molecule modulators",
abstract = "The RAS proteins play a role in cell differentiation, proliferation, and survival. Aberrant RAS signaling has been found to play a role in 30{\%} of all cancers. KRAS, a key member of the RAS protein family, is an attractive cancer target, as frequent point mutations in the KRAS gene render the protein constitutively active. A number of attempts have been made to target aberrant KRAS signaling by identifying small molecule compounds that (1) are synthetic lethal to mutant KRAS, (2) block KRAS/GEF interactions, (3) inhibit downstream KRAS effectors, or (4) inhibit the post-translational processing of RAS proteins. In addition, inhibition of novel targets outside the main KRAS signaling pathway, specifically the cell cycle related kinase PLK1, has been shown have an effect in cells that harbor mutant KRAS. Herein we review the use of various high-throughput screening assays utilized to identify new small-molecule compounds capable of targeting mutant KRAS-driven cancers.",
author = "Yuanxiang Wang and Kaiser, {Christine E.} and Brendan Frett and Li, {Hong Yu}",
year = "2013",
month = "7",
day = "11",
doi = "10.1021/jm3017706",
language = "English (US)",
volume = "56",
pages = "5219--5230",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "13",

}

TY - JOUR

T1 - Targeting mutant KRAS for anticancer therapeutics

T2 - A review of novel small molecule modulators

AU - Wang, Yuanxiang

AU - Kaiser, Christine E.

AU - Frett, Brendan

AU - Li, Hong Yu

PY - 2013/7/11

Y1 - 2013/7/11

N2 - The RAS proteins play a role in cell differentiation, proliferation, and survival. Aberrant RAS signaling has been found to play a role in 30% of all cancers. KRAS, a key member of the RAS protein family, is an attractive cancer target, as frequent point mutations in the KRAS gene render the protein constitutively active. A number of attempts have been made to target aberrant KRAS signaling by identifying small molecule compounds that (1) are synthetic lethal to mutant KRAS, (2) block KRAS/GEF interactions, (3) inhibit downstream KRAS effectors, or (4) inhibit the post-translational processing of RAS proteins. In addition, inhibition of novel targets outside the main KRAS signaling pathway, specifically the cell cycle related kinase PLK1, has been shown have an effect in cells that harbor mutant KRAS. Herein we review the use of various high-throughput screening assays utilized to identify new small-molecule compounds capable of targeting mutant KRAS-driven cancers.

AB - The RAS proteins play a role in cell differentiation, proliferation, and survival. Aberrant RAS signaling has been found to play a role in 30% of all cancers. KRAS, a key member of the RAS protein family, is an attractive cancer target, as frequent point mutations in the KRAS gene render the protein constitutively active. A number of attempts have been made to target aberrant KRAS signaling by identifying small molecule compounds that (1) are synthetic lethal to mutant KRAS, (2) block KRAS/GEF interactions, (3) inhibit downstream KRAS effectors, or (4) inhibit the post-translational processing of RAS proteins. In addition, inhibition of novel targets outside the main KRAS signaling pathway, specifically the cell cycle related kinase PLK1, has been shown have an effect in cells that harbor mutant KRAS. Herein we review the use of various high-throughput screening assays utilized to identify new small-molecule compounds capable of targeting mutant KRAS-driven cancers.

UR - http://www.scopus.com/inward/record.url?scp=84880169201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880169201&partnerID=8YFLogxK

U2 - 10.1021/jm3017706

DO - 10.1021/jm3017706

M3 - Article

C2 - 23566315

AN - SCOPUS:84880169201

VL - 56

SP - 5219

EP - 5230

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 13

ER -